End Of Financial Year Update, page-49

The big plus imo fellow BIG is US Centres ordering Cardiocel ahead of schedule.

Cardiocel is the worldwide number one Congenital Heart Defect patch without peer.

There's no speculation in regards to this and is grossly undervalued.

The worldwide market, especially the ASX haven't realised this and would rather risk their hard earned dollars investing in highly speculative products and investments.

In time they will look upon a missed chance at wealth creation just the same as a lot of well educated(in theory) brokers in regards to RHC, SEK and other masterfully run business's.

Cardiocel will be the number one by a country mile product for a whole range of surgical applications in the future.

My missus(IQ 141 and an ICU nurse) says the patch could be used to make and or repair organs of the body.

There practically isn't another company on the ASX with the calibre of directors with proven track records of running a successful listed entity.

We have a proven and approved world leading product/s, our own state of the art manufacturing plant and in time full ownership of a vaccine business headed by one of the worlds leading scientist in Ian Frazer already noted with proven success with Gardasil.

There is no doubt Admedus can achieve what is needed to become a billion dollar company in time.

They have always delivered and always have done everything in the best interestsof shareholders.

These companies are extremely rare.